πΊοΈ Anatomy - Mapping the Axilla
- Axillary Levels (Berg's Levels): Defined by their anatomical relationship to the Pectoralis Minor muscle, the key surgical landmark.
- Level I: Lymph nodes located lateral to the lateral border of the pectoralis minor.
- Level II: Nodes located posterior (deep) to the pectoralis minor muscle.
- Level III: Nodes located medial to the medial border of the pectoralis minor.

- Key Nerves at Risk:
- Long Thoracic Nerve: Innervates serratus anterior. Injury β winged scapula.
- Thoracodorsal Nerve: Innervates latissimus dorsi. Travels with thoracodorsal artery/vein. Injury β weak arm adduction & internal rotation.
- Intercostobrachial Nerve: Sensory nerve often sacrificed. Injury β numbness/paresthesia of medial upper arm and axilla.
β Lymphatic drainage typically flows sequentially: Level I β Level II β Level III. The long thoracic nerve is vulnerable as it runs along the chest wall on the surface of the serratus anterior.
πͺ Indications & Fallout
- Indications for ALND:
- Clinically positive (palpable, biopsy-proven) axillary nodes.
- Positive sentinel lymph node biopsy (SLNB) in patients planned for mastectomy or with β₯3 positive nodes.
- Inflammatory breast cancer (after neoadjuvant chemotherapy).
- Failed SLNB procedure (non-visualization of sentinel node).
- Fallout (Complications):
- Lymphedema: Most significant morbidity. Chronic arm swelling; risk ~20-30%.
- Nerve Injury:
- Long Thoracic n. β Winged Scapula (Serratus Anterior).
- Thoracodorsal n. β Weak arm adduction/extension (Latissimus Dorsi).
- Intercostobrachial n. β Medial arm numbness (most common injury).
- Other: Seroma, infection, shoulder stiffness, chronic pain.
β ACOSOG Z0011 Trial: For T1-T2 tumors with 1-2 positive sentinel nodes undergoing lumpectomy + whole-breast radiation, ALND offers no survival benefit over SLNB alone.
πͺ Management - The Surgical Blueprint
-
Indications for Axillary Lymph Node Dissection (ALND):
- Biopsy-proven nodal metastasis before surgery.
- Positive Sentinel Lymph Node Biopsy (SLNB), especially with β₯3 positive nodes.
- Clinically palpable, matted, or fixed axillary nodes.
- Inflammatory breast cancer.
- Failed SLNB mapping.
-
Surgical Boundaries (Levels I & II):
- Superior: Axillary vein (preserve).
- Lateral: Latissimus dorsi muscle.
- Medial: Pectoralis minor muscle.
- Anterior: Pectoralis major muscle.
-
β οΈ Nerves at Risk:
- Long Thoracic n.: Innervates serratus anterior. Injury β winged scapula.
- Thoracodorsal n.: Innervates latissimus dorsi. Injury β weak arm adduction/internal rotation.
- Intercostobrachial n.: Sensory. Injury β medial arm numbness.
β Injury to the long thoracic nerve is a classic complication tested on exams, leading to a "winged scapula" due to paralysis of the serratus anterior muscle.
- Major Complication: Chronic lymphedema.
π¬ Pathology - Grading the Haul
- Adequacy of Dissection: A minimum of 10 lymph nodes is required for accurate staging from a Level I/II ALND. Fewer nodes may lead to understaging.
- Pathologic Evaluation:
- Nodes are identified, counted, and sectioned for H&E staining.
- Immunohistochemistry (IHC) with cytokeratin antibodies can detect occult metastases.
- Metastasis Classification (AJCC):
- Macrometastases: >2.0 mm
- Micrometastases: 0.2 mm to 2.0 mm
- Isolated Tumor Cells (ITCs): <0.2 mm or <200 cells
- Extranodal Extension (ENE):
- Tumor invasion beyond the lymph node capsule.
- Associated with β risk of recurrence and β survival.
β The number of positive axillary lymph nodes is the single most powerful prognostic factor for recurrence and survival in early-stage, non-metastatic breast cancer.
β‘ Biggest Takeaways
- Indicated for biopsy-proven positive nodes or after a positive sentinel lymph node biopsy (SLNB).
- Standard dissection removes Level I and II axillary nodes; Level III is spared unless involved.
- Key nerve injuries: long thoracic (winged scapula), thoracodorsal (weak adduction), and intercostobrachial (medial arm numbness).
- Lymphedema is the most significant long-term complication.
- ACOSOG Z0011 trial supports omitting ALND in select patients with 1-2 positive SLNs undergoing breast-conserving therapy.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING β FREEor get the app